Bcl 2 Human (minus NWGR domain)
(b) Analysis by SDS-PAGE.
Description
The Bcl-2 is expressed as His-Tag fusion protein and purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
B-Cell Leukemia/Lymphoma 2 (BCL-2) is a protein that plays a crucial role in regulating apoptosis, or programmed cell death. This protein is part of the BCL-2 family, which includes both pro-apoptotic and anti-apoptotic members. The balance between these proteins determines whether a cell will undergo apoptosis. BCL-2 itself is an anti-apoptotic protein, meaning it helps cells avoid programmed death, which can be beneficial in normal cellular processes but problematic in cancer.
BCL-2 is located on the outer membrane of mitochondria, where it inhibits the release of cytochrome c, a key factor in the apoptotic pathway. By preventing cytochrome c release, BCL-2 effectively blocks the cascade of events leading to cell death. The protein has several domains, including BH1, BH2, BH3, and BH4, which are essential for its function and interactions with other proteins in the BCL-2 family.
The overexpression of BCL-2 is commonly observed in various types of cancer, including B-cell lymphomas and leukemias. This overexpression allows cancer cells to evade apoptosis, contributing to uncontrolled cell proliferation and tumor growth. Targeting BCL-2 has therefore become a strategy in cancer therapy, with several BCL-2 inhibitors being developed and tested in clinical trials.
The human recombinant BCL-2 (–NWGR) refers to a specific variant of the BCL-2 protein that has been engineered for research and therapeutic purposes. The “–NWGR” notation indicates a mutation or modification in the protein sequence, which can affect its function or interactions with other molecules. Recombinant proteins are produced using genetic engineering techniques, allowing for the study of specific protein variants and their roles in disease.
BCL-2 inhibitors, such as venetoclax, have shown promise in treating cancers that overexpress BCL-2. These inhibitors work by binding to the BCL-2 protein, preventing it from blocking apoptosis and thereby promoting the death of cancer cells. Clinical trials have demonstrated the effectiveness of BCL-2 inhibitors in treating chronic lymphocytic leukemia (CLL) and other B-cell malignancies .
